- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.62 Å
- Oligo State
- monomer
- Ligands
- 7 x PLM: PALMITIC ACID(Non-covalent)
PLM.1: 9 residues within 4Å:- Chain A: R.115, L.133, Y.136, L.137, A.156, Y.159, F.163, R.184
- Ligands: 8ZR.8
11 PLIP interactions:11 interactions with chain A- Hydrophobic interactions: A:R.115, A:Y.136, A:Y.136, A:Y.136, A:A.156, A:Y.159, A:Y.159, A:Y.159, A:Y.159, A:F.163
- Salt bridges: A:R.115
PLM.2: 16 residues within 4Å:- Chain A: L.12, L.20, V.21, V.44, L.64, L.67, F.68, Y.148, P.150, L.249, A.252, R.255, A.256, L.281, L.282, S.285
14 PLIP interactions:14 interactions with chain A- Hydrophobic interactions: A:L.12, A:L.20, A:V.21, A:V.44, A:L.64, A:L.67, A:F.68, A:P.150, A:A.252, A:L.281, A:L.282
- Hydrogen bonds: A:Y.148, A:S.285
- Salt bridges: A:R.255
PLM.3: 9 residues within 4Å:- Chain A: S.340, V.342, R.346, L.385, I.386, M.444, L.451, R.483
- Ligands: PLM.4
7 PLIP interactions:7 interactions with chain A- Hydrophobic interactions: A:V.342, A:L.385, A:I.386, A:L.451
- Hydrogen bonds: A:S.340
- Salt bridges: A:R.346, A:R.483
PLM.4: 12 residues within 4Å:- Chain A: L.385, Y.409, K.412, V.416, L.428, L.455, L.458, H.462, V.471, F.486, S.487
- Ligands: PLM.3
12 PLIP interactions:12 interactions with chain A- Hydrophobic interactions: A:Y.409, A:V.416, A:L.428, A:L.455, A:L.458, A:L.458, A:H.462, A:V.471, A:F.486
- Hydrogen bonds: A:S.487
- Salt bridges: A:R.408, A:K.412
PLM.5: 13 residues within 4Å:- Chain A: Y.399, N.403, F.505, K.523, A.526, L.530, H.533, V.545, M.546, F.549, A.550, S.577, Q.578
11 PLIP interactions:11 interactions with chain A- Hydrophobic interactions: A:F.505, A:F.505, A:K.523, A:A.526, A:L.530, A:L.530, A:V.545, A:F.549, A:F.549, A:Q.578
- Salt bridges: A:K.523
PLM.6: 7 residues within 4Å:- Chain A: R.207, A.208, K.210, V.214, D.322, L.325, K.349
4 PLIP interactions:4 interactions with chain A- Hydrophobic interactions: A:A.208, A:K.210, A:L.325
- Salt bridges: A:K.349
PLM.7: 10 residues within 4Å:- Chain A: K.197, W.212, L.217, V.239, H.240, R.255, L.258, I.262, S.285, I.288
8 PLIP interactions:8 interactions with chain A- Hydrophobic interactions: A:L.217, A:V.239, A:R.255, A:L.258, A:I.262, A:I.288
- Salt bridges: A:K.197, A:H.240
- 1 x 8ZR: ~{N},~{N},12-trimethyl-3$l^{3}-thia-1$l^{4},5,6$l^{4}-triaza-2$l^{3}-cupratricyclo[6.4.0.0^{2,6}]dodeca-1(8),3,6,9,11-pentaen-4-amine(Non-covalent)
8ZR.8: 12 residues within 4Å:- Chain A: R.112, L.113, I.140, R.143, H.144, F.147, F.155, Y.159, L.183, G.187, S.191
- Ligands: PLM.1
1 PLIP interactions:1 interactions with chain A,- Metal complexes: A:H.144
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Wang, J. et al., Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin. Mol. Pharm. (2018)
- Release Date
- 2018-09-05
- Peptides
- Serum albumin: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.62 Å
- Oligo State
- monomer
- Ligands
- 7 x PLM: PALMITIC ACID(Non-covalent)
- 1 x 8ZR: ~{N},~{N},12-trimethyl-3$l^{3}-thia-1$l^{4},5,6$l^{4}-triaza-2$l^{3}-cupratricyclo[6.4.0.0^{2,6}]dodeca-1(8),3,6,9,11-pentaen-4-amine(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Wang, J. et al., Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin. Mol. Pharm. (2018)
- Release Date
- 2018-09-05
- Peptides
- Serum albumin: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
B